United Therapeutics (UTHR) Property, Plant & Equipment (Net) Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Property, Plant & Equipment (Net) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | 4.65% |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | 5.45% |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | 5.00% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | -0.43% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 2.85% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 3.06% |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | -1.81% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 27.15% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 11.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.15% |
| Mar 31, 2026 | 27.10% |
| Dec 31, 2025 | 25.09% |
| Sep 30, 2025 | 22.76% |
| Jun 30, 2025 | 19.85% |
| Mar 31, 2025 | 18.42% |
| Dec 31, 2024 | 16.11% |
| Sep 30, 2024 | 16.76% |
| Jun 30, 2024 | 15.21% |
| Mar 31, 2024 | 14.59% |
| Dec 31, 2023 | 13.50% |
| Sep 30, 2023 | 10.45% |
| Jun 30, 2023 | 8.05% |
| Mar 31, 2023 | 6.64% |
| Dec 31, 2022 | 6.17% |
| Sep 30, 2022 | 7.42% |
| Jun 30, 2022 | 3.72% |
| Mar 31, 2022 | 3.81% |
| Dec 31, 2021 | 3.73% |
| Sep 30, 2021 | 2.99% |